Lifeboat Foundation

A US$500 billion accelerator of human progress — mansoor hanif, executive director, emerging technologies, NEOM.

Mansoor Hanif is the Executive Director of Emerging Technologies at NEOM (https://www.neom.com/en-us), a fascinating $500 billion planned cognitive city” & tourist destination, located in north west Saudi Arabia, where he is responsible for all R&D activities for the Technology & Digital sector, including space technologies, advanced robotics, human-machine interfaces, sustainable infrastructure, digital master plans, digital experience platforms and mixed reality. He also leads NEOM’s collaborative research activities with local and global universities and research institutions, as well as manages the team developing world-leading Regulations for Communications and Connectivity.

Continue reading “Mansoor Hanif — Executive Director, Emerging Technologies, NEOM — An Accelerator Of Human Progress” »

A need exists to accurately estimate overdose risk and improve understanding of how to deliver treatments and interventions in people with opioid use…

The Microsoft 365 Defender security research team discovered a new vulnerability in macOS that allows an attacker to bypass the System integrity protection or SIP. This is a critical security feature in macOS which uses kernel permissions to limit the ability to write critical system files. Microsoft explains that they also found a similar technique […].

The Microsoft 365 Defender security research team discovered a new vulnerability in macOS that allows an attacker to bypass the System integrity protection or SIP. This is a critical security feature in macOS which uses kernel permissions to limit the ability to write critical system files.

Microsoft explains that they also found a similar technique that could allow an attacker to gain elevated root privileges on an affected device, basically allowing to install a rootkit on macOS.

Displacing Delta. Expect this to dominate globally in the coming year, if truly 10% more transmissible.

An offshoot of the Delta coronavirus variant which is slowly spreading throughout the UK is expected to be dominant within a matter of months, experts believe.

Known as AY.4.2, the sub-variant is thought to be at least 10 cent more transmissible than its predecessor, with analysis underway to determine what accounts for its increased infectiousness.

Continue reading “Delta sub-variant expected to be dominant in UK” »

The world’s largest semiconductor manufacturers—Intel, Samsung, and the Taiwan Semiconductor Manufacturing Company (TSMC)—have all announced plans to build new chip factories in the US. Everyone is bragging about those plans: American lawmakers say bringing chip manufacturing back onto US soil will strengthen national security, while the chip makers, chastened by this year’s disastrous semiconductor shortage, are diversifying their supply chains to avoid future crises.

But there’s one problem: Who will pay?

Intel, Samsung, and TSMC have all threatened to pull the plug on their US factory plans unless government subsidies are on the table. Company executives claim that if they don’t get a rich package of incentives and tax breaks, they’ll build their semiconductor factories elsewhere, effectively ending American ambitions to return chip manufacturing to its shores after ceding the bulk of the market to Taiwan in the 1990s.

Facebook’s response, however, isn’t about how it should change its business model. Instead of any degree of self-awareness, the company has decided it’s going to push back on its critics and try to change the subject. Facebook isn’t actually trying to change any of the things that are wrong with Facebook.

Zuckerberg did talk a lot about the metaverse and said he plans to give more details later this week at Connect, the company’s developer conference.

To be fair, Zuckerberg did say that the company is “on track to spend more than $5 billion on safety and security in 2021.” That might sound impressive, but considering the company made $115 billion in the last 12 months, it’s barely anything. It’s only half of what Facebook says it plans to spend on building the metaverse.

AI & computational technology for improving drug discovery & development — mati gill, CEO, AION labs.

Mati Gill is the Chief Executive Officer, of AION Labs (https://aionlabs.com/), a company recently launched and backed by a coalition of pharma and tech leaders, including AstraZeneca, Merck, Pfizer, Teva, Amazon Web Services (AWS), and the Israel Biotech Fund (IBF) and Israel Innovation Authority, to improve the whole drug discovery & drug development process with AI and computational biology.

Continue reading “Mati Gill, CEO, AION Labs — AI & Computational Technology For Improving Drug Discovery & Development” »

Delta Air Lines expects 2.5 million passengers to move through the Atlanta airport during the Thanksgiving period. Ahead of the holiday rush, Delta is testing new facial recognition technology to reduce the time it takes between arriving at the airport and getting passengers in their seats.

The company’s senior vice president for customer experience, Ranjan Goswami, said the facial recognition technology has been years in the making and will speed up travel.

Recent advancements in biotechnology have immense potential to help address many global problems; climate change, an aging society, food security, energy security, and infectious diseases.

Biotechnology is not to be confused with the closely related field of biosciences. While biosciences refer to all the sciences that study and understand life, biology, and biological organisms, biotechnology refers to the application of the knowledge of biosciences and other technologies to develop tech and commercial products. Biotechnology is the application of innovation to biosciences in a bid to solve real-world medical problems.

Throw Artificial Intelligence into the mix and we suddenly have a really interesting pot of broth. Several AI trends have already proven beneficial to the development of biotechnology. Dr. Nathan S. Bryan, an inventor, biochemist and professor, who made a name for himself as an innovator and pioneer in nitric oxide drug discovery, commercialization, and molecular medicine, offers his insights on these contributions.